Bijun Sun1, Zeyu Zhu1,2, Xiaoying Hui1, Jinqiao Sun1, Wenjie Wang1, Wenjing Ying1, Qinhua Zhou1, Haili Yao1, Jia Hou3,4, Xiaochuan Wang5,6. 1. Department of Clinical Immunology, Children's Hospital of Fudan University, 399 Wanyuan Road, Shanghai, 201102, China. 2. Department of Clinical Medicine, Shanghai Medical College, Fudan University, Shanghai, 200032, China. 3. Department of Clinical Immunology, Children's Hospital of Fudan University, 399 Wanyuan Road, Shanghai, 201102, China. doctorhoujia@hotmail.com. 4. Department of Pediatrics, Shanghai Songjiang District Central Hospital, Shanghai, 201600, China. doctorhoujia@hotmail.com. 5. Department of Clinical Immunology, Children's Hospital of Fudan University, 399 Wanyuan Road, Shanghai, 201102, China. xchwang@shmu.edu.cn. 6. Shanghai Institute of Infectious Disease and Biosecurity, Shanghai, 200032, China. xchwang@shmu.edu.cn.
Abstract
PURPOSE: We aimed to report the clinical and immunological characteristics of variant type X91+ chronic granulomatous disease (CGD) in a Chinese cohort. METHODS: The clinical manifestations and immunological phenotypes of patients with X91+ CGD were collected. A dihydrorhodamine (DHR) analysis was performed to evaluate neutrophil function. Gp91phox protein expression was determined using extracellular staining with the monoclonal antibody (mAb) 7D5 and flow cytometry. RESULTS: Patients with X91+ CGD accounted for 8% (7/85) of all patients with CGD. The median age of onset in the seven patients with X91+ CGD was 4 months. Six patients received the BCG vaccine, and 50% (3/6) had probable BCG infections. Mycobacterium tuberculosis infection was prominent. The most common sites of infection were the lung (6/7), lymph nodes (5/7), and soft tissue (3/7). Two patients experienced recurrent oral ulcers. The stimulation index (SI) of the patients with X91+ CGD ranged widely from 1.9 to 67.3. The difference in the SI among the three groups of patients (X91+ CGD, X91- CGD, and X910 CGD) was statistically significant (P = 0.0071). The three groups showed no significant differences in onset age, diagnosis age, or severe infection frequency. CYBB mutations associated with X91+ CGD were commonly located in the second transmembrane or intracellular regions. Three novel X91+ CGD-related mutations (c.1462-2 A > T, c.1243C > T, and c.925G > A) were identified. CONCLUSIONS: Variant type X91+ CGD may result in varied clinical manifestations. Moreover, the laboratory findings might indicate a moderate neutrophil SI. We should deepen our understanding of variant X91+ CGD to prevent missed diagnoses.
PURPOSE: We aimed to report the clinical and immunological characteristics of variant type X91+ chronic granulomatous disease (CGD) in a Chinese cohort. METHODS: The clinical manifestations and immunological phenotypes of patients with X91+ CGD were collected. A dihydrorhodamine (DHR) analysis was performed to evaluate neutrophil function. Gp91phox protein expression was determined using extracellular staining with the monoclonal antibody (mAb) 7D5 and flow cytometry. RESULTS: Patients with X91+ CGD accounted for 8% (7/85) of all patients with CGD. The median age of onset in the seven patients with X91+ CGD was 4 months. Six patients received the BCG vaccine, and 50% (3/6) had probable BCG infections. Mycobacterium tuberculosis infection was prominent. The most common sites of infection were the lung (6/7), lymph nodes (5/7), and soft tissue (3/7). Two patients experienced recurrent oral ulcers. The stimulation index (SI) of the patients with X91+ CGD ranged widely from 1.9 to 67.3. The difference in the SI among the three groups of patients (X91+ CGD, X91- CGD, and X910 CGD) was statistically significant (P = 0.0071). The three groups showed no significant differences in onset age, diagnosis age, or severe infection frequency. CYBB mutations associated with X91+ CGD were commonly located in the second transmembrane or intracellular regions. Three novel X91+ CGD-related mutations (c.1462-2 A > T, c.1243C > T, and c.925G > A) were identified. CONCLUSIONS: Variant type X91+ CGD may result in varied clinical manifestations. Moreover, the laboratory findings might indicate a moderate neutrophil SI. We should deepen our understanding of variant X91+ CGD to prevent missed diagnoses.
Authors: D Roos; M de Boer; F Kuribayashi; C Meischl; R S Weening; A W Segal; A Ahlin; K Nemet; J P Hossle; E Bernatowska-Matuszkiewicz; H Middleton-Price Journal: Blood Date: 1996-03-01 Impact factor: 22.113
Authors: J H Leusen; C Meischl; M H Eppink; P M Hilarius; M de Boer; R S Weening; A Ahlin; L Sanders; D Goldblatt; H Skopczynska; E Bernatowska; J Palmblad; A J Verhoeven; W J van Berkel; D Roos Journal: Blood Date: 2000-01-15 Impact factor: 22.113
Authors: Lysann Mauch; Andreas Lun; Maurice R G O'Gorman; John S Harris; Ilka Schulze; Arturo Zychlinsky; Tobias Fuchs; Uta Oelschlägel; Sebastian Brenner; Dolphe Kutter; Angela Rösen-Wolff; Joachim Roesler Journal: Clin Chem Date: 2007-03-23 Impact factor: 8.327
Authors: Clara Bionda; Xing Jun Li; Robin van Bruggen; Michel Eppink; Dirk Roos; Françoise Morel; Marie-José Stasia Journal: Hum Genet Date: 2004-08-24 Impact factor: 4.132
Authors: Faris G Bakri; Cécile Martel; Najwa Khuri-Bulos; Azmi Mahafzah; Mohammad S El-Khateeb; Adel M Al-Wahadneh; Wail A Hayajneh; Hanan A Hamamy; Elisabeth Maquet; Michelle Molin; Marie José Stasia Journal: J Clin Immunol Date: 2008-09-05 Impact factor: 8.317
Authors: Jing Wang; Hui Yu; Victor Wei Zhang; Xia Tian; Yanming Feng; Guoli Wang; Elizabeth Gorman; Hao Wang; Richard E Lutz; Eric S Schmitt; Sandra Peacock; Lee-Jun Wong Journal: Genet Med Date: 2015-09-24 Impact factor: 8.822
Authors: Dirk Roos; Karin van Leeuwen; Amy P Hsu; Debra Long Priel; Amber Begtrup; Rhonda Brandon; Marie José Stasia; Faris Ghalib Bakri; Nezihe Köker; M Yavuz Köker; Manisha Madkaika; Martin de Boer; Maria Bravo Garcia-Morato; Juan Luis Valdivieso Shephard; Joachim Roesler; Hirokazu Kanegane; Toshinao Kawai; Gigliola Di Matteo; Mohammad Shahrooei; Jacinta Bustamante; Amit Rawat; Pandiarajan Vignesh; Esmaeil Mortaz; Abbas Fayezi; Deniz Cagdas; Ilhan Tezcan; Maleewan Kitcharoensakkul; Mary C Dinauer; Isabelle Meyts; Baruch Wolach; Antonio Condino-Neto; Christa S Zerbe; Steven M Holland; Harry L Malech; John I Gallin; Douglas B Kuhns Journal: Blood Cells Mol Dis Date: 2021-06-02 Impact factor: 3.039